Hookipa Pharma Stock Probability of Future Stock Price Finishing Over 7.4

HOOK Stock  USD 1.90  0.13  6.40%   
Hookipa Pharma's future price is the expected price of Hookipa Pharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Hookipa Pharma performance during a given time horizon utilizing its historical volatility. Check out Hookipa Pharma Backtesting, Hookipa Pharma Valuation, Hookipa Pharma Correlation, Hookipa Pharma Hype Analysis, Hookipa Pharma Volatility, Hookipa Pharma History as well as Hookipa Pharma Performance.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
  
Price Earnings To Growth Ratio is expected to rise to 0.08 this year, although the value of Price To Sales Ratio will most likely fall to 3.61. Please specify Hookipa Pharma's target price for which you would like Hookipa Pharma odds to be computed.

Hookipa Pharma Target Price Odds to finish over 7.4

The tendency of Hookipa Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 7.40  or more in 90 days
 1.90 90 days 7.40 
near 1
Based on a normal probability distribution, the odds of Hookipa Pharma to move over $ 7.40  or more in 90 days from now is near 1 (This Hookipa Pharma probability density function shows the probability of Hookipa Stock to fall within a particular range of prices over 90 days) . Probability of Hookipa Pharma price to stay between its current price of $ 1.90  and $ 7.40  at the end of the 90-day period is over 95.58 .
Given the investment horizon of 90 days Hookipa Pharma has a beta of 0.57. This usually indicates as returns on the market go up, Hookipa Pharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Hookipa Pharma will be expected to be much smaller as well. Additionally Hookipa Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Hookipa Pharma Price Density   
       Price  

Predictive Modules for Hookipa Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Hookipa Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.081.575.60
Details
Intrinsic
Valuation
LowRealHigh
0.132.616.64
Details
3 Analysts
Consensus
LowTargetHigh
4.394.825.35
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.61-0.61-0.61
Details

Hookipa Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Hookipa Pharma is not an exception. The market had few large corrections towards the Hookipa Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Hookipa Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Hookipa Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-1.27
β
Beta against Dow Jones0.57
σ
Overall volatility
0.81
Ir
Information ratio -0.32

Hookipa Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Hookipa Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Hookipa Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Hookipa Pharma generated a negative expected return over the last 90 days
Hookipa Pharma may become a speculative penny stock
Hookipa Pharma has high historical volatility and very poor performance
Hookipa Pharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 20.13 M. Net Loss for the year was (81.58 M) with loss before overhead, payroll, taxes, and interest of (52.97 M).
Hookipa Pharma currently holds about 117.92 M in cash with (57.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Hookipa Pharma has a poor financial position based on the latest SEC disclosures
Roughly 21.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Matushansky Igor of 8079 shares of Hookipa Pharma at 0.1 subject to Rule 16b-3

Hookipa Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Hookipa Stock often depends not only on the future outlook of the current and potential Hookipa Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Hookipa Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding9.5 M
Cash And Short Term Investments117.1 M

Hookipa Pharma Technical Analysis

Hookipa Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Hookipa Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Hookipa Pharma. In general, you should focus on analyzing Hookipa Stock price patterns and their correlations with different microeconomic environments and drivers.

Hookipa Pharma Predictive Forecast Models

Hookipa Pharma's time-series forecasting models is one of many Hookipa Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Hookipa Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Hookipa Pharma

Checking the ongoing alerts about Hookipa Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Hookipa Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Hookipa Pharma generated a negative expected return over the last 90 days
Hookipa Pharma may become a speculative penny stock
Hookipa Pharma has high historical volatility and very poor performance
Hookipa Pharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 20.13 M. Net Loss for the year was (81.58 M) with loss before overhead, payroll, taxes, and interest of (52.97 M).
Hookipa Pharma currently holds about 117.92 M in cash with (57.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Hookipa Pharma has a poor financial position based on the latest SEC disclosures
Roughly 21.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Matushansky Igor of 8079 shares of Hookipa Pharma at 0.1 subject to Rule 16b-3
When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:
Check out Hookipa Pharma Backtesting, Hookipa Pharma Valuation, Hookipa Pharma Correlation, Hookipa Pharma Hype Analysis, Hookipa Pharma Volatility, Hookipa Pharma History as well as Hookipa Pharma Performance.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.67)
Revenue Per Share
4.403
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.20)
Return On Equity
(0.49)
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.